

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 12/8/2008

Members Present: Bill Origer MD Chair, Nicole O’Kane PharmD, Cydreese Aebi PhD RPh, Rich Clark MD MPH, Tracy Klein FNP

Members Absent: Ruth Medak MD

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 107 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 8/6/2008. A motion to approve was made and passed unanimously.

3. Drugs for Constipation: Dr. Origer gave a presentation on the DERP report and its findings. The new report was discussed and the committee developed conclusion statements for the report.

Time was allotted for public testimony

The report “*Drugs for Constipation*” was unanimously accepted by the committee and referred to the HRC for review.

4. Meeting Adjournment: Meeting was adjourned by Chair Origer at 8:55 pm. Next meeting date TBD.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 7/2/2008

Members Present: Bill Origer MD Chair, , Nicole O’Kane PharmD, Cydreese Aebi PhD RPh,, Tracy Klein FNP, WHCNP

Members Absent: Ruth Medak MD, Rich Clark MD MPH

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 107 of the Meridian Park Health Education Center, Tualatin, Oregon.

2.Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 6/18/2008. A motion to approve was made and passed unanimously.

3. Second generation Antidepressants: Dr. Origer gave a presentation on the DERP report and its findings. The new report was discussed and the committee developed conclusion statements for the report.

Time was allotted for public testimony

The report “Second Generation Antidepressants” was unanimously accepted by the committee and referred to the HRC for review.

4. Meeting Adjournment: Meeting was adjourned by Chair Origer at 9:05 pm. Next meeting scheduled for August 6, 2008.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 6/18/2008

Members Present: Bill Origer MD Chair, , Nicole O’Kane PharmD, Cydreese Aebi PhD RPh., Tracy Klein FNP, WHCNP

Members Absent: Ruth Medak MD, Rich Clark MD MPH

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 107 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the subcommittee members to review the minutes of 5/14/2008. A motion to approve was made and passed unanimously.

3. Drugs for ADHD: Dr. Origer gave a presentation on the DERP report and its findings. The new report was discussed and the committee developed conclusion statements for the report.

Time was allotted for public testimony

The report “Drugs for ADHD” was unanimously accepted by the committee and referred to the HRC for review.

4. Second Generation Antidepressants: Dr. Origer gave a presentation on the DERP report and its findings. At that time the committee voted to defer further discussion to the next meeting due to the time and their desire for staff to consolidate proposed conclusions into a different format.

There was no public testimony

5. Meeting Adjournment: Meeting was adjourned by Chair Origer at 9:25 pm. Next meeting scheduled for July 2, 2008.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 5/14/2008

Members Present: Bill Origer MD Chair, , Nicole O’Kane PharmD, Cydreese Aebi PhD RPh., Rich Clark MD MPH

Members Absent: Ruth Medak MD, Tracy Klein FNP, WHCNP

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 107 of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Approval of Minutes: Dr. Origer asked the members to review the minutes of 4/9/2008 the group. A motion to approve was made and passed unanimously.

3. Disease-modifying drugs for MS: Dr. Origer gave a presentation on the DERP report and its findings. The new report was discussed and the committee developed consensus statements and conclusions for the report.

Time was allotted for public testimony

The report “Disease-modifying drugs for MS” was unanimously accepted by the committee and referred to the HRC for review.

4. Report format discussion: There was discussion surrounding ways to make the reports more useable. Discussion revolved around re-organization to put an “abstract” of the report up front to contain a synopsis and conclusions in approximately one to two pages. This would also be made available on a stand alone basis as a “Physician/prescriber” information source. Discussion also included the removal of repetitive materials from the body of the report such as the discussion of SB 819 and moving this to a single site on the HRC website with a link from each report. This will eliminate many unnecessary pages from each report while retaining the availability to the information for anyone who wishes to read it.

5. Meeting Adjournment: Meeting was adjourned by Chair Origer at 8:45 pm.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 4/9/2008

Members Present: Bill Origer MD Chair, Nicole O’Kane PharmD, Cydreese Aebi PhD RPh, Tracy Klein FNP, WHCNP, Rich Clark MD MPH
Members Absent: Ruth Medak MD, Tracy Klein FNP

Staff Present: David Pass M.D,

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 107 of the Meridian Park Health Education Center, Tualatin, Oregon.

2.Approval of Minutes: Dr. Origer asked the members to review the minutes of 3/4/2008 the group. A motion to approve was made and passed unanimously.

3. Hormone Replacement Therapy (HRT) Update #3: Dr. Origer gave a presentation of the new changes to this report since the last update. The committee discussed the changes to the HRT report. There was a significant change from the last report in that the key questions had been modified from the previous editions.. Additional changes and updates were agreed on by consensus.

Time was allotted for public testimony

The updated report “Hormone Replacement update #3” was unanimously accepted by the committee and referred to the HRC for review.

4.Fixed Dose Combination products for Hyperlipidemia and Type 2 Diabetes: Dr. Origer gave a presentation on the class of drugs covered in the DERP report for this drug class. The new report was discussed and the committee developed consensus statements and conclusions.

Time was allotted for Public testimony

The report “Fixed Dose Combination Products for Hyperlipidemia and Type 2 Diabetes” was unanimously accepted by the committee and referred to the HRC for review.

5. Meeting Adjournment: Meeting was adjourned by Chair Origer at 9:00 pm.

Health Resources Commission
Pharmaceutical subcommittee
Minutes from 3/4/2008

Members Present: Bill Origer MD Chair, Ruth Medak MD, Nicole O’Kane PharmD, Cydreese Aebi PhD RPh, Tracy Klein FNP

Members Absent: Rich Clark MD

Staff Present: David Pass M.D.

1. Call to Order: Chairperson Bill Origer called the meeting to order at 6:30pm. Meeting was held in room 117bc of the Meridian Park Health Education Center, Tualatin, Oregon.

2. Introductions: Dr. Origer asked the members to introduce themselves to the group.

3. Beta Blocker Update #3: Dr. Origer gave a presentation of the new changes to this report since the last update. The committee discussed the changes to the Beta Blocker report. There was one new drug, carvedilol phosphate (ER), and a new indication for nadolol in migraine therapy. Additional changes and updates were agreed on by consensus.

Time was allotted for public testimony

The updated report “Beta Adrenergic Blockers update #3” was unanimously accepted by the committee and referred to the HRC for review.

4. Drugs for Neuropathic Pain: Dr. Origer gave a presentation on the class of drugs covered in the DERP report for this drug class. The new report “Drugs for Neuropathic Pain” was discussed and the committee developed consensus statements and conclusions.

Time was allotted for Public testimony

The report “drugs for Neuropathic Pain” was unanimously accepted by the committee and referred to the HRC for review.

5. Meeting Adjournment: Meeting was adjourned by Chair Origer at 9:15 pm.